ACHE and Alzheimer disease: Cholinomimetic drugs, especially AChE inhibitors, have been the first line of defense in AD treatment for many years, and as mentioned above, their benefits are thought to be due to a synaptic increase in ACh or direct stimulation of ACh receptors.